A cyclic peptide made from repeating tryptophan and arginine units successfully delivered three different types of cargo into cells without toxicity, showing promise as a versatile drug delivery vehicle.
3 cargo types deliveredThe cyclic peptide [WWRR]5 transported a phosphopeptide, siRNA, and an antiviral drug into cells — all without toxicity
What the researchers found
Researchers designed eight peptides — four linear and four cyclic — built from repeating tryptophan-tryptophan-arginine-arginine (WWRR) units and tested them as molecular delivery vehicles. The cyclic peptide [WWRR]5 (called C4) was the clear winner, showing the highest cellular uptake of three different cargo molecules including a phosphopeptide, siRNA, and an antiviral drug (3TC).
None of the peptides showed significant toxicity to cells at 5 μM concentration. The uptake of C4 was concentration- and time-dependent, and entered cells through both energy-dependent (endocytosis) and energy-independent pathways, confirming it acts as a true cell-penetrating peptide.
Why it matters
Many promising drugs can't get inside cells because they're too large or too negatively charged to cross cell membranes. Cell-penetrating peptides solve this by acting as molecular taxis that carry cargo across the membrane. This study's cyclic [WWRR]5 peptide successfully delivered three very different types of cargo — a peptide, an RNA molecule, and a small drug — suggesting it could be a versatile delivery platform for therapeutics that otherwise can't reach their intracellular targets.
The numbers in context
8 peptides tested · 5 μM with no significant cytotoxicity · 3 cargo types delivered · 3 cell lines tested (MDA-MB-231, SK-OV-3, HEK 293) · 4 endocytosis inhibitors used
How the study worked
Lab-based study synthesizing eight peptides (four cyclic, four linear) with alternating WW and RR residues of varying lengths. Cytotoxicity was assessed in three cell lines. Cellular uptake of fluorescence-labeled cargo was measured using flow cytometry and confocal microscopy. Endocytosis inhibitors were used to determine the uptake mechanism.
Who was studied
In vitro study using cancer cell lines (MDA-MB-231 breast cancer, SK-OV-3 ovarian cancer) and normal human cells (HEK 293)
What this study cannot tell us
Entirely in vitro — no animal or human testing. Tested at only one peptide concentration (5 μM) for toxicity. No comparison with established cell-penetrating peptides like TAT or penetratin. Long-term stability, immunogenicity, and in vivo behavior are unknown.
How to read the evidence
Preliminary evidence from cell-based experiments only. While the results are promising and the study design is solid for early-stage research, there is no animal or human data. The findings need validation in more complex biological systems before clinical relevance can be assessed.
When this study was published
Published in 2023. This is recent work in the active field of cell-penetrating peptide design. The cyclic WWRR peptide template is new and likely still being developed by this research group.
The bigger picture
Cell-penetrating peptides are one of the hottest areas in drug delivery research because they could unlock the therapeutic potential of large molecules like siRNA, gene therapies, and peptide drugs that can't cross cell membranes on their own. This study adds a new design template — alternating tryptophan and arginine in cyclic form — to the growing toolkit. The fact that C4 delivered three structurally different cargoes suggests it may be more versatile than peptide transporters designed for a single cargo type.
Questions still open
- How does [WWRR]5 compare to established cell-penetrating peptides like TAT or penetratin in terms of delivery efficiency?
- Will the cyclic peptide maintain its delivery ability and safety profile in animal models?
- Can the [WWRR] design template be optimized further for specific cargo types or target tissues?
Common questions
What is a cell-penetrating peptide and why does it matter?
Why did the cyclic version work better than the linear version?
Read the original research
Cyclic and Linear Peptides Containing Alternate WW and RR Residues as Molecular Cargo Delivery Tools.
Molecular pharmaceutics, 20(1), 341-356
Citation
Kim, Lois; Lohan, Sandeep; Moreno, Jonathan; Zoghebi, Khalid; Tiwari, Rakesh Kumar; Parang, Keykavous. (2023). Cyclic and Linear Peptides Containing Alternate WW and RR Residues as Molecular Cargo Delivery Tools.. Molecular pharmaceutics, 20(1), 341-356. https://doi.org/10.1021/acs.molpharmaceut.2c00664